The thiopurine methyltransferase TPMT *1/*3A genotype is associated with a better treatment outcome in the UK ALL97 trial for childhood acute lymphoblastic leukaemia; TPMT heterozygosity is not associated with secondary cancers
Päätekijät: | , , , , , , , , |
---|---|
Aineistotyyppi: | Conference item |
Julkaistu: |
2010
|
Yhteenveto: |
---|